Non-arteritic anterior ischaemic optic neuropathy (NA-AION) and COVID-19 vaccination
- PMID: 35568418
- PMCID: PMC9109041
- DOI: 10.1136/bcr-2021-248415
Non-arteritic anterior ischaemic optic neuropathy (NA-AION) and COVID-19 vaccination
Abstract
A woman in her 50s presented with diminution of vision in her left eye (OS) 4 days after COVISHIELDTM vaccination. She had been diagnosed with non-arteritic anterior ischaemic optic neuropathy (NA-AION) of right eye (OD) 8 months earlier. The present episode revealed a best-corrected visual acuity (BCVA) of 20/50 in OD and 20/20 in OS with grade 1 relative afferent pupillary defect. Fundus evaluation showed pale disc in OD and temporal disc oedema in OS. Humphrey's visual field analysis showed incomplete inferior altitudinal defect in OD and a centro-caecal scotoma in OS. Systemic investigations were normal. OS was diagnosed with NA-AION. She was started on oral aspirin 75 mg. At 1-month follow-up, disc oedema of OS had resolved with BCVA maintaining at 20/20. The patient was lost to follow-up later. The relationship between the vaccine and the ocular event is temporal with no causal association.
Keywords: COVID-19; Eye; Immunological products and vaccines; Medical management; Neuroopthalmology.
© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
References
-
- The impact of COVID-19 on global health goals, 2021. Available: https://www.who.int/news-room/spotlight/the-impact-of-covid-19-on-global... [Accessed 21 Jan 2022].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical